Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome

Gynecological Endocrinology

Volumn 22, Issue 1, 2006, Pages 36-43

  Genazzani, Alessandro D ^a   Strucchi, Claudia ^a   Luisi, Michele ^b   Casarosa, Elena ^b   Lanzoni, Chiara ^a   Baraldi, Enrica ^c   Ricchieri, Federica ^a   Mehmeti, Hilda ^a   Genazzani, Andrea R ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Allopregnanolone; Cortisol; Hyperinsulinemia; Metformin cloridate; Polycystic ovary syndrome

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ANDROGEN; HYDROCORTISONE; INSULIN; LUTEINIZING HORMONE; METFORAL; METFORMIN; NEUROSTEROID;

ADRENAL FUNCTION; ADULT; AMENORRHEA; ANDROGEN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FUNCTIONAL ASSESSMENT; HORMONAL REGULATION; HORMONE DETERMINATION; HUMAN; INFORMED CONSENT; INSULIN RESISTANCE; MENSTRUAL CYCLE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PULSATILE HORMONE RELEASE; STEROID RELEASE; STEROIDOGENESIS;

ADULT; ANALYSIS OF VARIANCE; ANDROGENS; FEMALE; GLUCOSE TOLERANCE TEST; GONADOTROPINS, PITUITARY; HUMANS; HYDROCORTISONE; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LINEAR MODELS; METFORMIN; POLYCYSTIC OVARY SYNDROME; PREGNANOLONE;

EID: 33644829248     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590500476164     Document Type: Article

References (43)

1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-3082.
2. Lucky AW, Rosenfield RL, McGuire J, Rudy S, Helke J. Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche. J Clin Endocrinol Metab 1986;62:840-848.
3. Moran C, Reyna R, Boots LS, Azziz R. Adrenocortical hyperresponsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgens excess. Fertil Steril 2004;81:126-131.
4. Ovalle F, Azziz R. Insulin resistance, the polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 2002;77:1095-1105.
5. Nardo LG, Rai R. Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects. Gynecol Endocrinol 2001;15:373-380.
6. Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986;62:904-910.
7. Heaney D, Majid A, Junor B. Bicarbonate haemodialysis as a treatment of metformin overdose. Nephrol Dial Transplant 1997;12:1046-1047.
8. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333:541-549.
9. Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 2004;81:114-119.
10. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876-1880.
11. Vanky E, Kjotrod SB, Maesel A, Bjerve KS, Carlsen SM. Dexamethasone reduces androgen levels in metformin-treated patients with polycystic ovary syndrome. Fertil Steril 2004;81:459-462.
12. Baulieu EE, Robel P. Neurosteroids: a new brain function? J Steroid Biochem Mol Biol 1990;37:395-403.
13. Paul SM, Purdy RH. Neuroactive steroids. FASEB J 1992;6:2311-2322.
14. Mellon SH, Deschepper CF. Neurosteroid biosynthesis: genes for adrenal steroidogenic enzymes are expressed in the brain. Brain Res 1993;629:283-292.
15. Robel P, Baulieu EE. Neurosteroids: biosynthesis and function. Trends Endocrinol Metab 1994;5:1-8.
16. Genazzani AR, Petraglia F, Bernardi F, Casarosa E, Salvestroni C, Tonetti A, Nappi RE, Luisi S, Palumbo M, Purdy RH, et al. Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences. J Clin Endocrinol Metab 1998;83:2099-2103.
17. Corpechot C, Young J, Calvel M, Wehrey C, Veltz JN, Touyer G, Mouren M, Prasad VV, Banner C, Sjovall J. Neurosteroids: 3α-hydroxy-5α- pregnan-20-one and its precursor in the brain, plasma, and steroidogenic glands of male, and female rats. Endocrinology 1993;133:1003-1009.
18. Genazzani AD, Luisi M, Malavasi B, Strucchi C, Luisi S, Casarosa E, Bernardi F, Genazzani AR, Petraglia F. Pulsatile secretory characteristics of allopregnanolone, a neuroactive steroid, during the menstrual cycle and in amenorrheic subjects. Eur J Endocrinol 2002;146:347-356.
19. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000;73:1149-1154.
20. Legro RS, Finegood D, Dunaif A. Fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:2694-2698.
21. Genazzani AD, Petraglia F, Fabbri G, Monzani A, Montanini V, Genazzani AR. Evidence of luteinizing hormone secretion in hypothalamic amenorrhea associated with weight loss. Fertil Steril 1990;54:222-226.
22. Genazzani AD, Petraglia F, Benatti R, Montanini V, Algeri I, Volpe A, Genazzani AR. Luteinizing hormone (LH) secretory burst duration is independent from LH, prolactin or gonadal steroid plasma levels in amenorrheic women. J Clin Endocrinol Metab 1991;72:1220-1225.
23. Genazzani AD, Stomati M, Bernardi F, Pieri M, Rovati L, Genazzani AR. Long-term low-dose dehydro-epiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids. Fertil Steril 2003;80:1495-1501.
24. Genazzani AD, Petraglia F, Pianazzi F, Volpogni C, Genazzani AR. The concomitant release of androstenedione with cortisol and luteinizing hormone pulsatile releases distinguishes adrenal from ovarian hyperandrogenism. Gynecol Endocrinol 1993;7:33-41.
25. Oerter KE, Guardabasso V, Rodbard D. Detection and characterization of peaks and estimation of instantaneous secretory rate for episodic pulsatile hormone secretion. Comput Biomed Res 1986;19:170-191.
26. Genazzani AD. Application of peak-detection programs to clinical data. In: Guardabasso V, Rodbard D, Forti G, editors. Computers in endocrinology: Recent advances. New York: Raven Press; 1990. pp 71-82.
27. Genazzani AD, Rodbard D. Evaluation of methods for detection of pulsatile hormone secretion: sensitivity vs. specificity. Acta Endocrinol (Copenh) 1991;124:295-306.
28. Guardabasso V, Genazzani AD, Veldhuis JD, Rodbard D. Objective assessment of concordance of secretory events in two endocrine time-series. Acta Endocrinol (Copenh) 1991;124:208-218.
29. Ibanez L, Valls C, Ferrer A, Ong K, Dunger DB, De Zengher F. Additive effects of insulin-sensitizing and anti-androgen treatment in young, non obese women with hyperinsulinism, hyperandrogenism, dyslipidemia and anovulation. J Clin Endocrinol Metab 2002;87:2870-2874.
30. Ibanez L, Valls C, Ferrer A, Marcos MV, Rodriguez Hierro F, De Zengher F. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 2001;86:3595-3598.
31. Taylor AE. Polycystic ovary syndrome. Endocrinol Metab Clin North Am 1998;27:877-902.
32. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
33. La Marca A, Egbe TO, Morgante G, Paglia T, Ciani A, De Leo V. Metformin treatment reduces ovarian cytochrome P-450c17α: response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome. Hum Reprod 2000;15:21-23.
34. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HN. Metformin therapy improves the menstrual pattern with minimal endocrine metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998;69:691-696.
35. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenism and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647-654.
36. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 1999;72:282-285.
37. De Leo V, La Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003;24:633-667.
38. Faray-Ewans L, Reyna R, Knochenhauer ES, Bartolucci AA, Azziz R. Glucose action and adrenocortical biosynthesis in women with polycystic ovary syndrome. Fertil Steril 2004;81:120-125.
39. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J 1986;293:355-359.
40. Clayton RN, Ogden V, Hodgkinson J, Worswick L, Rodin DA, Dyer S, Meade TW. How common are polycystic ovaries in normal women and what is their significance for the fertility of the population? Clin Endocrinol (Oxf) 1992;37:127-134.
41. Genazzani AD, Petraglia F, Battaglia C, Gamba O, Volpe A, Genazzani AR. A long-term treatment with gonadotropin-releasing hormone agonist plus a low-dose oral contraceptive improves the recovery of the ovulatory function in patients with polycystic ovary syndrome. Fertil Steril 1997;67:463-468.
42. De Leo V, La Marca A, Orvieto R, Morgante G. Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein I in polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:1598-1600.
43. Genazzani AD, Battaglia C, Gamba O, Petraglia F, Malavasi B, Genazzani AR. The use of a combined regimen of GnRH agonist plus a low-dose oral contraceptive improves the spontaneous pulsatile LH secretory characteristics in patients with polycystic ovary disease after discontinuation of treatment. J Assist Reprod Genet 2000;17:269-275.